BBZAD Stock Overview
An equity fund launched and managed by Bellevue Asset Management AG.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
BB Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 39.40 |
| 52 Week High | CHF 51.80 |
| 52 Week Low | CHF 37.95 |
| Beta | 0.84 |
| 11 Month Change | 2.74% |
| 3 Month Change | -5.06% |
| 1 Year Change | -2.96% |
| 33 Year Change | -48.31% |
| 5 Year Change | n/a |
| Change since IPO | 213.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| BBZAD | GB Capital Markets | GB Market | |
|---|---|---|---|
| 7D | -0.1% | -1.2% | -1.3% |
| 1Y | -3.0% | 29.3% | 8.9% |
Return vs Industry: BBZAD underperformed the UK Capital Markets industry which returned 29.3% over the past year.
Return vs Market: BBZAD underperformed the UK Market which returned 8.9% over the past year.
Price Volatility
| BBZAD volatility | |
|---|---|
| BBZAD Average Weekly Movement | 3.1% |
| Capital Markets Industry Average Movement | 3.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BBZAD has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine BBZAD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 10 | n/a | www.bbbiotech.ch/en/bb-biotech/ |
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.
BB Biotech AG Fundamentals Summary
| BBZAD fundamental statistics | |
|---|---|
| Market cap | €2.15b |
| Earnings (TTM) | €133.37m |
| Revenue (TTM) | €47.36m |
16.1x
P/E Ratio45.4x
P/S RatioIs BBZAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBZAD income statement (TTM) | |
|---|---|
| Revenue | CHF 44.51m |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 44.51m |
| Other Expenses | -CHF 80.85m |
| Earnings | CHF 125.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | 2.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | 281.64% |
| Debt/Equity Ratio | 12.3% |
How did BBZAD perform over the long term?
See historical performance and comparison